The Role of Artificial Intelligence in Clarifying Unexpected Outcomes in Cancer Clinical Trials

In an article authored by Maurie Markman, the potential of artificial intelligence to examine medical records in explaining unexpected results emerging from randomized cancer clinical trials is opened to discussion.

Artificial Intelligence and the Healthcare Sector

The role of artificial intelligence technology in many areas of healthcare, including oncology, continues to rapidly expand. New products are announced every month with the aim of increasing operational efficiency or assisting in the detection of various human disorders.

Assumptions in Cancer Research

When randomized studies are designed to examine current standard of care options versus investigational approaches in cancer care, certain assumptions are necessary to ensure comparable populations within the study arms.

Unexpected Study Outcomes

When objective findings seriously call these assumptions into question, in cases where an experimental regimen performs significantly worse than the control arm, a clear explanation may not always be found.

Examples in Gynecological Oncology

In the field of gynecological oncology, two previously published phase 3 randomized trials demonstrate that questions have remained unanswered due to reasons such as the time elapsed since the reported results and the lack of medical records.

Canfosfamide and PLD Studies

In a phase 3 study examining the novel agent called canfosfamide, the investigative regimen yielded statistically inferior results, whereas a striking overall survival benefit was observed in the comparison between pegylated liposomal doxorubicin and topotecan.

Potential Solutions for the Future

It is being questioned whether AI-based medical record reviews can discover overlooked details to explain these surprising outcomes and assist in future drug development efforts.